Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study-Reference-Cited by-同舟云学术

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study

Published:2006-09 Issue:9539 Volume:368 Page:919-928
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Deedwania Prakash,Barter Philip,Carmena Rafael,Fruchart Jean-Charles,Grundy Scott M,Haffner Steven,Kastelein John JP,LaRosa John C,Schachner Holly,Shepherd James,Waters David D

Publisher

Elsevier BV

Subject

General Medicine

Reference28 articles.

1. Clustering of heart disease risk factors in diabetic compared to nondiabetic adults;Wingard;Am J Epidemiol,1983

2. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease;Stern;Arteriosclerosis,1986

3. Banting lecture 1988. Role of insulin resistance in human disease;Reaven;Diabetes,1988

4. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study;Sattar;Circulation,2003

5. Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease?;Deedwania;Circulation,2004

Cited by 329 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of lipid abnormalities in metabolic syndrome;Metabolic Syndrome;2024

2. Special Patient Populations;Clinical Lipidology;2024

3. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis;Cochrane Database of Systematic Reviews;2023-11-29

4. Moderate‐intensity statin with ezetimibe combination therapy versus high‐intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post‐hoc analysis of the RACING trial;Diabetes, Obesity and Metabolism;2023-11-23

5. Effectiveness of icosapent ethyl on first and total cardiovascular events in patients with metabolic syndrome, but without diabetes: REDUCE-IT MetSyn;European Heart Journal Open;2023-11